Phase 3 Trial Completion (2026) Before Eli Lilly can ask for approval, it needs to finish its main trials
This glucose-dependent action reduces the risk of hypoglycaemia compared to some other diabetes medications
Moitra M, Santomauro D, Collins PY, Vos T, Whiteford H, Saxena S, et al
And Chris says he has gotten his share of cease-and-desist letters from the brand name manufacturers
An analysis of self-funded plans by one of our partners showed that if a 250-person company chooses to cover GLP-1s for weight loss, even assuming a lifetime maximum of $18,000, they can expect to see a total claims increase of 5%
However, be aware that the cost can be high